|
|
 |
New Research - July 2009
More on beta-adrenergic receptor polymorphisms and their effect on receptivity to beta-andrenergic therapy
There has been controversy as to whether or not point mutations in the beta-adrenergic receptor can be associated with decreased responses to beta-adrenergic agents. Previously, point mutations at position 16 ( Arg/Arg or Arg/Gly vs Gly/Gly) have been shown to alter responsiveness to beta-adrenergic agents.
The authors of this investigation evaluated beta-receptor polymorphisms in children aged 2 to 18 years. They looked at patients admitted to a hospital with severe asthma, requiring intensive care. They found that subjects with the Gly/Gly genotype fared better than those with Arg/Gly or Arg/Arg genotypes. The Gly/Gly subjects required less albuterol, less oxygen and were less likely to receive intravenous beta-adrenergic treatment. They also spent less time in the intensive care unit.
Reference
Carroll CL, et al. Beta2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. Chest 2009; 135:1186-1192.
<back>
|
